Online inquiry

IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3663MR)

This product GTTS-WQ3663MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F11 gene. The antibody can be applied in Thromobosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000128.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2160
UniProt ID P03951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3663MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15710MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ10224MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ2407MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ8162MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL036337
GTTS-WQ672MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 8H9
GTTS-WQ4099MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ5246MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ12758MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-52M51
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW